Immunostaining for the Tregs marker FoxP3 and CD4 in the corresponding bulk tissue samples confirmed a higher number of Tregs among the CD4+ tumour infiltrating lymphocytes (TIL) (Fig. 3c), which was most prominent in those patients predicted to have a higher proportion of Tregs as assessed by CS/DS biosynthetic pathway deregulation (Fig. S7a). This evidence concerns the gene FOXP3 and neoplasm.